OncoVent, a Subsidiary of Hepalink and Orient EuroPharma Enters into a License and Distribution Agreement to Develop and Commercialize Oregovomab in Taiwan
Shots:
- OncoVent to receive a total transaction amount of $11.2M incl. a one-off non-refundable upfront payment upon the effective date of the license agreement along with multiple regulatory and commercial milestone payments
- Through the exclusive right, granted by OncoVent, Orient will be responsible for the clinical trials, regulatory submissions, and commercialization of oregovomab in Taiwan and has rights to first refusal for the exclusive sales, marketing, and distribution in Hong Kong and Macau
- Oregovomab, a murine mAB, and anti-CA125 immunotx., is currently being evaluated in a P-III study, expected to enroll patients (n=602) at 190 clinical sites in 17 countries
Ref: Shenzhen Hepalink | Image: Oncovent
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
